Spasm, endoscopy of the genito-urinary tract or gastro- intestinal tract, Irritable Bowel Syndrome

Active Ingredient: Butylscopolamine

Indication for Butylscopolamine

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Butylscopolamine is indicated for the relief of spasm of the genito-urinary tract or gastro-intestinal tract and for the symptomatic relief of Irritable Bowel Syndrome. It can also be given during endoscopy of the gastrointestinal and urinary tract.

For this indication, competent medicine agencies globally authorize below treatments:

30mg in 3 divided doses

Route of admnistration

Rectal

Defined daily dose

30 mg

Dosage regimen

10 mg 3 time(s) per day every day

30-80mg in 3-4 divided doses daily

Route of admnistration

Oral

Defined daily dose

30 - 80 mg

Dosage regimen

From 10 To 26.667 mg 3 time(s) per day every day

Detailed description

Adults: 20mg four times daily. For the symptomatic relief of Irritable Bowel Syndrome, the recommended starting dose is 10mg three times daily, this can be increased up to 20mg four times daily if necessary.

20 mg initially with the possibility of an additional dose up to a daily maximum of 100 mg

Route of admnistration

Intravenous

Defined daily dose

20 - 100 mg

Dosage regimen

From 20 To 100 mg once every day

Detailed description

In acute painful conditions and endoscopy of the digestive tract, a dose of 20 mg in subcutaneous, intramuscular or intravenous injection, repeatable in half to one hour, if necessary. The maximum daily dose should not exceed 100 mg.

20 mg initially with the possibility of an additional dose up to a daily maximum of 100 mg

Route of admnistration

Subcutaneous

Defined daily dose

20 - 100 mg

Dosage regimen

From 20 To 100 mg once every day

Detailed description

In acute painful conditions and endoscopy of the digestive tract, a dose of 20 mg in subcutaneous, intramuscular or intravenous injection, repeatable in half to one hour, if necessary. The maximum daily dose should not exceed 100 mg.

20 mg initially with the possibility of an additional dose up to a daily maximum of 100 mg

Route of admnistration

Intramuscular

Defined daily dose

20 - 100 mg

Dosage regimen

From 20 To 100 mg once every day

Detailed description

In acute painful conditions and endoscopy of the digestive tract, a dose of 20 mg in subcutaneous, intramuscular or intravenous injection, repeatable in half to one hour, if necessary. The maximum daily dose should not exceed 100 mg.

Active ingredient

Butylscopolamine

Butylscopolamine is an antispasmodic agent which relaxes smooth muscle of the organs of the abdominal and pelvic cavities. It is believed to act predominantly on the intramural parasympathetic ganglia of these organs.

Read more about Butylscopolamine

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.